Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Dr Reddys Lab
Join Channel
Consolidated Standalone

Dr. Reddy's Lab

₹5812.5 13.3 | 0.2%

Market Cap ₹96963 Cr.

Stock P/E 17.4

P/B 4

Current Price ₹5812.5

Book Value ₹ 1453.1

Face Value 5

52W High ₹6505.5

Dividend Yield 0.69%

52W Low ₹ 4383.4

Edit Ratio

Dr. Reddy's Lab Research see more...

Overview Inc. Year: 1984Industry: Pharmaceuticals & Drugs

Dr. Reddy's Laboratories Limited is an India-based pharmaceutical corporation. The Company's segments consist of Global Generics, which is engaged in production and marketing prescription and over the counter finished pharmaceutical merchandise ready for consumption by patient, marketed under a brand name (branded formulations) or as usual finished dosages with healing equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and advertising and marketing active pharmaceutical elements and intermediates for finished pharmaceutical merchandise; Proprietary Products, which focuses on studies and development of differentiated formulations and Others, which includes the Company's absolutely-owned subsidiary, Aurigene Discovery Technologies Ltd, which is a discovery stage biotechnology organisation growing novel and treatments in the fields of oncology and inflammation.

Read More..

Dr. Reddy's Lab Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Dr. Reddy's Lab Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Dr. Reddy's Lab Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 8434 9728 10011 10292 9720 9359 10626 11850 13349 14405 16963
Other Income 146 218 224 325 658 261 274 743 801 482 591
Total Income 8580 9946 10235 10617 10378 9621 10899 12594 14150 14887 17554
Total Expenditure 6448 7005 7620 8227 8041 8087 8361 8981 10212 11811 12748
Operating Profit 2132 2942 2615 2390 2337 1534 2538 3613 3938 3076 4806
Interest 66 107 65 64 57 63 57 48 47 38 17
Depreciation 313 381 490 650 735 774 781 789 835 814 923
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 1753 2454 2060 1677 1545 697 1701 2776 3056 2224 3866
Provision for Tax 488 522 381 302 160 130 423 -162 870 601 1253
Profit After Tax 1266 1933 1679 1374 1384 567 1277 2938 2186 1623 2613
Adjustments 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 1266 1933 1679 1374 1384 567 1277 2938 2186 1623 2613
Adjusted Earnings Per Share 74.5 113.6 98.6 80.6 83.5 34.2 76.9 176.8 131.4 97.5 156.8

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 18% 13% 13% 7%
Operating Profit CAGR 56% 10% 26% 8%
PAT CAGR 61% -4% 36% 8%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 31% 4% 18% 10%
ROE Average 14% 12% 14% 14%
ROCE Average 19% 16% 16% 15%

Dr. Reddy's Lab Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 7783 9329 10634 12078 11601 11808 12684 15192 16984 18336 20474
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 6 902 939 994 485 488 345 19 18 20 29
Other Non-Current Liabilities 1851 2378 2860 61 21 -9 139 -529 -187 75 432
Total Current Liabilities 4073 4114 4679 4389 4258 4720 3079 4181 4560 6045 4440
Total Liabilities 13714 16723 19112 17522 16365 17007 16248 18863 21375 24476 25375
Fixed Assets 2387 2748 3249 4438 4842 4717 4683 4434 5844 6151 7207
Other Non-Current Assets 4727 5067 5459 2873 2929 3251 2632 4322 4586 4829 4486
Total Current Assets 6600 8908 10403 10211 8594 9039 8933 10107 10944 13494 13682
Total Assets 13714 16723 19112 17522 16365 17007 16248 18863 21375 24476 25375

Dr. Reddy's Lab Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 140 56 116 68 202 67 121 113 39 1305 1160
Cash Flow from Operating Activities 289 906 1786 2747 1016 1539 2762 1839 3514 1339 5053
Cash Flow from Investing Activities -519 -881 -2017 -1910 1443 -1180 -551 -1689 -1458 -2038 -3448
Cash Flow from Financing Activities 152 28 189 -693 -2582 -304 -2223 -224 -794 506 -2697
Net Cash Inflow / Outflow -78 53 -41 144 -123 54 -12 -74 1262 -194 -1092
Closing Cash & Cash Equivalent 56 116 60 202 67 121 113 39 1305 1160 112

Dr. Reddy's Lab Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 74.53 113.56 98.56 80.56 83.48 34.15 76.95 176.76 131.39 97.55 156.83
CEPS(Rs) 92.95 135.92 127.32 118.63 127.82 80.78 123.97 224.24 181.57 146.48 212.24
DPS(Rs) 15 18 20 20 20 20 20 25 25 30 40
Book NAV/Share(Rs) 454.35 543.33 618.75 702.68 694.83 706.34 759.31 907.83 1013.05 1093.32 1220.2
Core EBITDA Margin(%) 23.35 27.76 23.69 20.07 17.27 13.6 21.31 24.22 23.5 18.01 24.85
EBIT Margin(%) 21.38 26.11 21.05 16.91 16.48 8.12 16.54 23.83 23.24 15.7 22.89
Pre Tax Margin(%) 20.61 25.02 20.41 16.29 15.89 7.45 16.01 23.42 22.89 15.44 22.79
PAT Margin (%) 14.88 19.7 16.64 13.35 14.24 6.06 12.02 24.79 16.38 11.27 15.4
Cash Profit Margin (%) 18.56 23.58 21.49 19.66 21.8 14.33 19.37 31.45 22.63 16.92 20.85
ROA(%) 9.98 12.7 9.37 7.5 8.17 3.4 7.68 16.73 10.87 7.08 10.48
ROE(%) 17.6 22.79 16.97 12.2 11.78 4.88 10.5 21.22 13.69 9.26 13.57
ROCE(%) 20.06 23.41 16.5 12.04 11 5.36 12.49 18.58 17.81 11.68 18.91
Receivable days 105.29 140 167.66 152.52 155.75 167.87 136.06 128.69 119.2 114.34 99.35
Inventory Days 61.22 58.02 59.94 60.7 65.89 71.49 66.51 64.77 68.49 78.14 68.76
Payable days 95.03 98.27 83.2 88.52 99.98 121.14 119.58 100.38 99.93 102.62 115.51
PER(x) 23.7 22.55 35.39 37.67 31.53 60.98 36.05 17.63 34.37 44.14 29.47
Price/Book(x) 3.89 4.71 5.64 4.32 3.79 2.95 3.65 3.43 4.46 3.94 3.79
Dividend Yield(%) 0.85 0.7 0.57 0.66 0.76 0.96 0.72 0.8 0.55 0.7 0.87
EV/Net Sales(x) 3.7 4.69 6.16 5.31 4.73 3.96 4.42 4.49 5.6 4.99 4.5
EV/Core EBITDA(x) 14.62 15.5 23.58 22.87 19.66 24.15 18.52 14.73 18.97 23.35 15.9
Net Sales Growth(%) 25.14 15.34 2.91 2.81 -5.56 -3.71 13.53 11.53 12.65 7.91 17.75
EBIT Growth(%) 36.91 40.81 -17.04 -18.07 -7.99 -52.56 131.31 60.66 9.89 -27.11 71.67
PAT Growth(%) 38.7 52.73 -13.11 -18.17 0.71 -59.04 125.31 129.99 -25.57 -25.76 60.97
EPS Growth(%) 38.54 52.37 -13.21 -18.26 3.63 -59.09 125.31 129.72 -25.66 -25.76 60.77
Debt/Equity(x) 0.27 0.29 0.3 0.26 0.2 0.22 0.08 0.1 0.07 0.12 0
Current Ratio(x) 1.62 2.17 2.22 2.33 2.02 1.91 2.9 2.42 2.4 2.23 3.08
Quick Ratio(x) 1.25 1.78 1.86 1.94 1.59 1.52 2.25 1.89 1.78 1.68 2.4
Interest Cover(x) 27.77 24.02 32.84 27.16 28 12.1 30.94 59.07 66.44 59.52 229.76
Total Debt/Mcap(x) 0.07 0.06 0.05 0.06 0.05 0.07 0.02 0.03 0.02 0.03 0

Dr. Reddy's Lab Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 26.72 26.72 26.71 26.71 26.7 26.7 26.69 26.66 26.65 26.65
FII 27.42 25.16 25.87 26.26 27.29 27.25 27 28.2 28.62 29.14
DII 22.29 24.78 25.19 24.7 23.38 23.05 21.99 21.04 18.65 18.31
Public 12.04 12.12 11.87 12.26 12.1 11.7 11.78 10.09 10.74 10.55
Others 11.53 11.23 10.37 10.08 10.53 11.3 12.54 14.02 15.33 15.35
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has delivered good profit growth of 35% CAGR over last 5 years
  • Company is almost debt free.

Cons

  • Promoter holding is low: 26.65%.
  • Company has a low return on equity of 12% over the last 3 years.
  • Debtor days have increased from 102.62 to 115.51days.
  • Stock is trading at 4 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Dr. Reddy's Lab News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!